Biotalys NV · EURONEXT:BTLS
Biotalys NV — Investor Presentation (November 2022)
27 slides from Biotalys NV's investor presentation, November 2022
Slide 1: Shaping a sustainable and safe food supply
Shaping a sustainable and safe food supply November 2022
Slide 2: Biotalys' mission is to address food loss and safety concerns
Biotalys’ mission is to address food loss and safety concerns Challenges Requirements Biotalys’ solutions Differentiated and versatile 9.5b population by 20501 biocontrol platform Secure yields and +50 % food required by 2050 1 minimize food loss Innovative modes of action to fight resistance 2X siz
Slide 3: Safe harbor statement
Safe harbor statement This presentation, including the oral presentation (together, the “Materials”) has been prepared by the management of Biotalys NV (the “Company”). The Materials must be treated confidentially and may not be distributed, passed on or otherwise disclosed. The Materials serve info
Slide 4: Shaping the future of sustainable and safe food supply
Shaping the future of sustainable and safe food supply Approval of Founded in 2013 Belgium and US 20 patent 75 FTEs1 first product IPO in 2021 locations families1 expected early 2023 Agricultural Technology company Developing novel protein-based The first product Evoca™,2 aims to focused on addressi
Slide 5: AGROBODY Foundry Platform
AGROBODY FoundryTM Platform
Slide 6: AGROBODY – validated platform for the generation of antibody-based biocontrols
AGROBODY™ – validated platform for the generation of antibody-based biocontrols Similar affinity to conventional antibodies Single domain antibodies engineered from heavy-chain antibodies exploited for >25 years → High binding capacity to selected antigens VHH High stability Heavy-chain antibody → E
Slide 7: AGROBODY Foundry: nature driven, designed for performance
AGROBODY FoundryTM: nature driven, designed for performance Current key crop pest and disease targets High Throughput Targeted Discovery Field Straightforward Delivery Development Regulatory Path Fungi Antibody inspired protein libraries Insects Deliver novel Bacteria biocontrols for Identify top wi
Slide 8: AGROBODY Foundry combines the best of both worlds
AGROBODY Foundry™ combines the best of both worlds Sustainability Performance Discovery A numbers game Scalability Efficiency5 Consistency 108 Antibodies Thousands of hits ~ €30m2 Multiple potential leads & diverse MoA 8 years3 100,000 Synthesis €250m1 Chemicals 1 Lead + Backups (same MoA) 11 years1
Slide 9: Biotalys' first biofungicide: Evoca
Biotalys’ first biofungicide: Evoca™ EvocaTM is pending registration. This product is not currently registered for sale or use in the United States, the EU or elsewhere, and 9 is not being offered for sale.
Slide 10: Evoca – A novel tool for biocontrol
Evoca™ – A novel tool for biocontrol Performance on par with Contact activity for preventive synthetic chemical standards in IPM*- control of Botrytis cinerea (bunchrot) programs1 and powdery mildew New mode-of-action for resistance management: replacement of Up to 2/3 of residue reduction in IPM 1
Slide 11: Independent field trials by US public institutes in 2021
Independent field trials by US public institutes in 2021 Continued demonstration of performance and consistency in independent IPM programs Grape – Botrytis bunch rot (UC Davis Cooperative Extension – Dr. Akif Eskalen) Source: https://ucanr.edu/sites/eskalenlab/files/357290.pdf Untreated EVOCA™ Lead
Slide 12: Latest field trial results validate Evoca's strength
Latest field trial results validate Evoca’s strength Evoca™ outperforms leading chemical in suppressing bunch rot Meta-analysis performed across 8 wine/table grape 60 trials in 2021 across diverse climates c b a 40 Evoca™ substituted at flowering in an IPM program Key Finding Bunch rot severity at h
Slide 13: Evoca – On track towards Market Calibration
Evoca™ – On track towards Market Calibration U.S. EPA decision expected New classification by the Market ready: exclusive early 2023 Fungicide Resistance Action distribution partner for Committee (FRAC) U.S. - Biobest Dossier passed both the provided Evoca™ has the potential to complement Biobest is
Slide 14: Evoca: Ongoing efforts are further increasing manufacturing efficiency
Evoca™: Ongoing efforts are further increasing manufacturing efficiency Stable process for Evoca™ meets High quality and Exploring new repetitive production at scale grower practice consistency from robust manufacturing routes within regulatory specs fermentation process 5 batches meeting Best-in-cl
Slide 15: Product Pipeline
NOT FOR DISTRIBUTION Product Pipeline
Slide 16: Innovative pipeline of protein-based biocontrols
Innovative pipeline of protein-based biocontrols Target Program Total Addressable Stage Target Crops Partnerships Market2 Launch3 Botrytis, Powdery mildew Market calibration 2023 Botrytis, Powdery mildew $600m 2026 Botrytis, Powdery mildew, Anthracnose BioFun-61 $1.2bn 2028 Lepidoptera BioIns-1 $800
Slide 17: Multi-year grant by the Bill & Melinda Gates Foundation
Multi-year grant by the Bill & Melinda Gates Foundation • Research into leafspot disease for cowpeas supporting smallholders livelihood • Targeting discovery of a new, safe and efficient protein-based bio-fungicide • 4 years grant as of 2022 • Additional non-dilutive funding of USD 6 million • Poten
Slide 18: De-risk, accelerate and grow through strategic partnerships
De-risk, accelerate and grow through strategic partnerships Science and Technology Product Development Distribution Exclusive US Pipeline Product Manufacturing Regulatory 18
Slide 19: Continued exploration of potential applications throughout the food value chain
Continued exploration of potential applications throughout the food value chain Seed treatment Around harvest Retail Crop Protection Post-harvest Covered Other crops Segments ... Ag Industry Majors Food Protection Retail Distributors Shipper packers Consumers Biocontrol Specialists Integrated Food i
Slide 20: Financials
Financials reinventing food protection
Slide 21: Key financials – HY 2022
Key financials – HY 2022 In € thousand June 30, 2022 June 30, 2021 Other operating income 1,140 831 Research and development expenses (7,574) (6,275) General and administration expenses (2,596) (2,241) Marketing expenses (718) (677) Operating loss (9,748) (8,363) Loss of the period (9,892) (7,158) N
Slide 22: Investor events
Investor events Kepler KBCS Berenberg World VFB Soirée Cheuvreux L’Investisseur Sustainability Food & Chem AgriTech Webinar Autumn on Tour Conference Conference Innovation 27 October Conference 26 September 29 September 13 September 21 September (virtual) 15 September (Brussels) (virtual) (London) (
Slide 23: Listed on Euronext Brussels
Listed on Euronext Brussels Code: Analyst coverage: BTLS Gimv 14.00 % Guy Sips KBC Securities Sofinnova 13.70 % AvH 13.00 % Christian Faitz PMV 8.10 % Kepler Cheuvreux AIF 7.00 % Sebastian Bray Shareholder Biovest 6.70 % Berenberg structure Madeli 6.30 % K&E 6.10 % Other 25.20 % Percentages rounded
Slide 24: Value creation designed through pipeline advancement, strategic key partnerships & commercial growth
Value creation designed through pipeline advancement, strategic key partnerships & commercial growth Sales In-licensing growth to accelerate and market AGROBODY growth expansion Pipeline Foundry™ progression expansion Strategic R&D and Evoca™ partnerships expansion registration Strategic production
Slide 25: Outlook: continuous value creation with major milestones
Outlook: continuous value creation with major milestones • Obtain 1st generation product approval in the US, paving the way to advance the rest of Biotalys’ pipeline through the regulatory process • Initiate market calibration in the US with partner Biobest for highest F&V market segment Evoca • Pro
Slide 26: Our team
Our team Patrice Sellès Luc Maertens Wim Ottevaere Patrick McDonnell Carlo Boutton CEO COO CFO CBO CSO 26
Slide 27: IR@biotalys.com www.biotalys.com
IR@biotalys.com www.biotalys.com